Navigation Links
New Agreements Underscore QIAGEN's Leadership in Bioinformatics
Date:2/2/2016

HILDEN, Germany and AARHUS, Denmark, February 2, 2016 /PRNewswire/ --

FDA centers and researchers gain access to QIAGEN's enhanced solutions for applications including microbial and microbiome analysis

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new partnerships to enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications.

QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID, Inc. to allow users of QIAGEN's CLC Genomics Workbench to access and integrate CosmosID's metagenomics analysis platform into their QIAGEN bioinformatics platform. CosmosID's platform allows users to identify and characterize microbial communities from whole genome shotgun data and to determine their relative abundance. The new plug-in expands the range of metagenomic and microbiome applications supported by QIAGEN's microbial genomics solution enabling researchers in fields such as infectious disease, animal health, agriculture, environmental and food safety to use shotgun metagenomics analysis for routine testing employing next-generation sequencing.

Click here for full press release

Public Relations:
Dr. Thomas Theuringer
Director Public Relations
+49-2103-29-11826
+1-240-686-7425
Email: pr@qiagen.com
http://www.twitter.com/qiagen
https://www.facebook.com/QIAGEN
pr.qiagen.com

Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222
Email: ir@qiagen.com


'/>"/>
SOURCE QIAGEN NV
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. QIAGEN Reaches Milestone With Portfolio of Master Collaboration Agreements for Pharma Companion Diagnostics
2. Agreements & Partnerships, a Key Strategy Adopted by Leading Market Players to Foster their Growth in the Global Oncology Information System Market - MarketsandMarkets
3. Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)
4. Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
5. Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech, and Diagnostics
6. A Revelation on Asset Purchase Terms and Agreements in Pharma, Biotech, and Diagnostics
7. Molecular Diagnostics Partnering Terms and Agreements : Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz
8. Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us
9. Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
10. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline
11. Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... ... July 09, 2020 , ... In most research ... to suppress pigment formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic ... MA has been using the zebrafish model to investigate the causes of leukaemia ...
(Date:7/7/2020)... ... 06, 2020 , ... Bio-IT World has announced the winners ... the University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance ... highlighting outstanding examples of how technology innovations and strategic initiatives can be powerful ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight ... microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. (“Lumeda”), ... announced the company has entered a license agreement with Roswell Park Comprehensive Cancer ... exclusive rights to Roswell Park intellectual property surrounding a novel medical device and ...
Breaking Biology Technology:
(Date:8/23/2020)... , ... August 21, 2020 , ... ... Corporation has been published and is now available on the company’s global ... diffraction—serves the X-ray analysis community, presenting current news and crystallographic research. , ...
(Date:8/21/2020)... ... 20, 2020 , ... NDA Partners Chairman Carl Peck, ... with expertise in clinical trial planning and feasibility, regulatory inspection readiness, and clinical ... his career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, and ...
(Date:8/7/2020)... ... August 06, 2020 , ... Nine ... prestigious National STEM Scholar Program, a unique professional development program that provides advanced ... for middle school science teachers nationwide. , Created in partnership between the National ...
Breaking Biology News(10 mins):